Skip to main content
. 2023 Sep 17;38:101790. doi: 10.1016/j.tranon.2023.101790

Fig. 7.

Fig 7

SLC38A5 dominates an inflamed and immunosuppressive TME. (a, b) KM survival curves of OS between patients with a high expression of SLC38A5 and with a low expression of SLC38A5 in the TCGA-KIRC (a) and E-MTAB-1980 cohorts (b). (c) The distribution of the expression of SLC38A5 across stages I to IV. (d) The distribution of the expression of SLC38A5 across subclusters of CAFs and malignant cells. (e) The distribution of activi-ties of anti-cancer immunity cycles between patients with a high expression of SLC38A5 and with a low expression of SLC38A5. (f) The expression levels of immune checkpoints CD274, CD80, CD86, CTLA-4, PDCD1 (PD-1), and PDCD1LG2 (PD-L2) between patients with a high expression of SLC38A5 and with a low expression of SLC38A5. (g) The distribution of the expression of SLC38A5 across immune subtypes C1 to C6. C1: wound healing, C2: IFN-γ dominant, C3: inflammatory, C4: lymphocyte depleted, C5: immu-nologically quiet, and C6: TGF-βdominant.